XIFIN is led by a highly skilled executive team that has extensive experience in healthcare diagnostics and financial management. The team is focused on delivering innovative solutions that improve the quality and economics of healthcare.
The XIFIN Medical Advisory Board provides industry perspective and strategic counsel impacting XIFIN product and market strategy.
XIFIN's highly resourceful Board of Directors has a proven track record of guiding successful, high-growth companies with a combination of industry leadership, deep sector expertise, and long-term growth strategies.
Executive Chairman & CEO
Lâle White, CEO and founder of XIFIN, is dedicated to the vision of optimizing the economics of healthcare – creating an environment in which patients receive the best healthcare at the lowest cost to themselves and the healthcare system as a whole. Since founding the company in 1997, she has helped diagnostic labs and health systems process more than 60 million lab visits per year, realizing more than $3 billion in cumulative net cash collection gains.
Lâle is a nationally recognized expert in the field of medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major labs and lab associations throughout the U.S. She has chaired the state and federal contractor committees for California Clinical Laboratory Association (CCLA) for years, maintaining a working relationship with the Department of Health and Human Services. Lâle has also worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
Prior to founding XIFIN, Lâle held leadership roles with Laboratory Corporation of America and National Health Laboratories. She has held Board of Directors memberships with bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017.
Lâle has been recognized with multiple industry and business honors including the lifetime achievement award from the CCLA, the Entrepreneur of the Year Award from Ernst & Young and inclusion in the Top 50 Women Entrepreneurs in America from Inc. She has a BA in finance and an MBA from Florida International University.
Managing Partner and Co-CEO, Avista Capital Partners
David Burgstahler is Managing Partner and Co-Chief Executive Officer of Avista Capital Partners. Prior to co-founding Avista Capital Partners in 2005, he was a partner of DLJ Merchant Banking Partners and head of healthcare. David was at DLJ Investment Banking from 1995 to 1997 and DLJMB from 1997 to 2005. Prior to joining DLJ, he worked at McDonnell Douglas (now Boeing) from 1987 to 1990 and Andersen Consulting (now Accenture) from 1991 to 1993. David received a BS in Aerospace Engineering from the University of Kansas and an MBA from Harvard Business School. David currently serves as a director of several companies in addition to XIFIN, including Arcadia Consumer Healthcare, Cosette Pharmaceuticals, Inform Diagnostics, Osmotica Pharmaceuticals (Nasdaq: OSMT), and United BioSource Corporation. He previously served on the boards of AngioDynamics (Nasdaq: ANGO), Armored AutoGroup, BioReliance, ConvaTec Group, Focus Diagnostics, INC Research Holdings (Nasdaq: INCR), Lantheus Holdings (Nasdaq: LNTH), MPI Research, Inc., Strategic Partners, Visant, Warner Chilcott (Nasdaq: WCRX) and WideOpenWest (NYSE: WOW). David is also a trustee of the Trinity School in New York City.
Partner, Avista Capital Partners
Sriram Venkataraman is a partner at Avista Capital Partners, having joined the organization in 2007. Prior to joining Avista, Sriram was a vice president in the Healthcare Investment Banking group at Credit Suisse. Prior to Credit Suisse, he worked at GE Healthcare (formerly known as GE Medical Systems). In addition to serving on XIFIN’s board, Sriram currently serves as a director of Cosette Pharmaceuticals, Inform Diagnostics, National Spine & Pain Centers, OptiNose (NASDAQ: OPTN), and Osmotica Pharmaceuticals (NASDAQ: OSMT), and previously served as a director of AngioDynamics (NASDAQ: ANGO), Lantheus Holdings (NASDAQ: LNTH) and Zest Dental Solutions. Sriram received a MS in Electrical Engineering from the University of Illinois, Urbana-Champaign and an MBA with honors from The Wharton School at the University of Pennsylvania.
Principal, Avista Capital Partners
Alex Yu is a principal at Avista Capital Partners, having joined the firm in 2017. Prior to joining Avista, Alex worked in the private equity group at Goldman Sachs. Prior to joining Goldman Sachs, he worked as an associate at Fenway Partners and as an analyst in the technology group at Lehman Brothers and Barclays Capital. Alex received a BA from Northwestern University and an MBA with honors from The Wharton School at the University of Pennsylvania. He currently serves as a director of Acino International AG, Arcadia Consumer Healthcare, Inform Diagnostics and XIFIN and previously served as a director of Trimb Healthcare.
Vice President, Avista Capital Partners
Garrett Lustig is a vice president at Avista Capital Partners. Garrett joined Avista Capital Partners in 2015. Prior to joining Avista, Garrett worked as an investment banking analyst at Centerview Partners. He received a BS in Economics from Duke University.
William Klitgaard currently serves on the board of directors at Syneos Health (formerly INC Research/Inventiv Health) and Certara, in addition to XIFIN. Previously, he served on the boards of Liaison Technologies, ICR Research, and Bioclinica. William also served as president of Enlighten Health, a division of LabCorp focused on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance. Previously, he spent 19 years at Covance, one of the world’s largest contract research organizations, where he served for three years as Corporate Senior Vice President and Chief Information Officer and nearly 12 years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, William held finance leadership positions at Kenetech Corporation and Consolidated Freightways, Inc. William completed his undergraduate studies in economics at the University of California at Berkeley, followed by his master’s degree at the Sloan Management School, Massachusetts Institute of Technology.